drugset / Trial / NCT04503902
Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study is an open, multi-center phase I/II clinical study.
Timeline
- Start
- 2020-10-15
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 100 mg | Oral |
| Subject | Donafenib | Small molecule | 200 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |